MCID: DMY001
MIFTS: 46

Demyelinating Polyneuropathy

Categories: Muscle diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 11 14
Peripheral Demyelinating Neuropathy 11 71
Demyelinating Peripheral Neuropathy 5

Classifications:



External Ids:

Disease Ontology 11 DOID:5214
NCIt 49 C27062
SNOMED-CT 68 23414001
UMLS 71 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary: Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Demyelinating Polyneuropathy is LRCH2 (Leucine Rich Repeats And Calponin Homology Domain Containing 2), and among its related pathways/superpathways are Nervous system development and Neuroscience. The drugs Immunoglobulin G and Glycine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone marrow and brain, and related phenotypes are Increased gamma-H2AX phosphorylation and Increased viability

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Subacute Inflammatory Demyelinating Polyneuropathy Acute and Subacute Inflammatory Demyelinating Polyneuropathy
Chronic Acquired Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
# Related Disease Score Top Affiliating Genes
1 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 33.2 SOX10 PMP22 MPZ GJB1 EGR2
2 chronic inflammatory demyelinating polyradiculoneuropathy 32.7 PMP22 NFASC MYOM2 MUSK MPZ MBP
3 guillain-barre syndrome 32.6 PMP22 MPZ MOG MBP ALB
4 polyneuropathy 31.7 TTR PMP22 NFASC MYOM2 MPZ MBP
5 polyradiculoneuropathy 31.6 PMP22 MPZ MBP ALB
6 neuropathy 31.4 SOX10 PMP22 NFASC MPZ GJB1 EGR2
7 roussy-levy hereditary areflexic dystasia 31.3 PMP22 MPZ
8 hereditary neuropathies 31.2 PMP22 MPZ MAG GJB1
9 tooth disease 31.2 PMP22 MPZ GJB1 EGR2
10 neuropathy, hereditary, with liability to pressure palsies 31.1 PMP22 MPZ MAG GJB1 EGR2
11 sensory peripheral neuropathy 31.0 PMP22 MPZ MAG GJB1 EGR2 ALB
12 motor peripheral neuropathy 31.0 PMP22 MAG KIF5A
13 monoclonal gammopathy of uncertain significance 31.0 MYOM2 MAG ALB
14 demyelinating disease 31.0 MPZ MOG MBP MAG AQP4
15 diabetic neuropathy 31.0 PMP22 MPZ ALB
16 chronic polyneuropathy 31.0 PMP22 MAG
17 bell's palsy 30.9 MBP ALB
18 facial paralysis 30.8 MOG MBP AQP4 ALB
19 myelitis 30.7 MOG MBP AQP4
20 neuritis 30.7 PMP22 MPZ MOG MBP MAG AQP4
21 carpal tunnel syndrome 30.7 TTR PMP22 MPZ
22 polyradiculopathy 30.7 NFASC MAG GLDN CNTNAP1 CNTN1
23 mononeuropathy 30.7 TTR PMP22 MPZ MAG GJB1 ALB
24 autoimmune neuropathy 30.6 NFASC MPZ MAG GLDN CNTNAP1 CNTN1
25 charcot-marie-tooth disease, demyelinating, type 1b 30.6 PMP22 MPZ GJB1 EGR2
26 cranial nerve palsy 30.6 MOG AQP4 ALB
27 charcot-marie-tooth disease, demyelinating, type 1a 30.6 SOX10 PMP22 MPZ MBP MAG GJB1
28 nerve compression syndrome 30.6 TTR PMP22 MPZ ALB
29 neuropathy, congenital hypomyelinating, 1, autosomal recessive 30.6 SOX10 PMP22 MPZ KIF5A GLDN GJB1
30 amyotrophic lateral sclerosis 1 30.5 TTR MUSK MOG MBP MAG KIF5A
31 charcot-marie-tooth disease 30.5 TTR SOX10 PMP22 NFASC MPZ MBP
32 abducens palsy 30.5 MUSK MOG AQP4
33 papilledema 30.5 MYOM2 MOG AQP4 ALB
34 optic neuritis 30.5 MPZ MOG MBP MAG AQP4
35 osteosclerotic myeloma 30.4 MYOM2 MAG
36 metachromatic leukodystrophy 30.4 MPZ MBP MAG
37 miller fisher syndrome 30.4 NFASC MUSK MOG MAG CNTN1 AQP4
38 optic nerve disease 30.4 MOG MBP MAG AQP4 ALB
39 median neuropathy 30.4 TTR PMP22 NFASC
40 charcot-marie-tooth disease and deafness 30.4 SOX10 PMP22 MPZ MBP MAG GJB1
41 wallerian degeneration 30.4 MPZ MAG
42 neuromuscular disease 30.4 SOX10 PMP22 MUSK MPZ MBP MAG
43 progressive multifocal leukoencephalopathy 30.4 MOG MBP AQP4
44 neuromyelitis optica 30.3 MOG MBP AQP4
45 spinal cord disease 30.3 MOG MBP AQP4 ALB
46 autoimmune peripheral neuropathy 30.3 NFASC MPZ MAG CNTN1
47 charcot-marie-tooth disease, x-linked dominant, 1 30.3 PMP22 MPZ GJB1 EGR2
48 plexopathy 30.2 PMP22 NFASC MUSK MPZ MAG
49 meningoencephalitis 30.2 MOG MBP ALB
50 acute disseminated encephalomyelitis 30.2 MOG MBP MAG AQP4

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

GenomeRNAi Phenotypes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased gamma-H2AX phosphorylation GR00053-A 9.76 COA3 EGR2 GJB1 MAG MBP MOG
2 Increased viability GR00386-A-1 9.02 LRCH2 MAG MBP MYOM2 SOX10
3 Decreased viability in pancreas lineage GR00235-A 8.96 MPZ MUSK

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.24 AQP4 CNTN1 CNTNAP1 EGR2 GJB1 GLDN
2 behavior/neurological MP:0005386 10.06 AQP4 CNTN1 CNTNAP1 EGR2 GJB1 GLDN
3 cellular MP:0005384 10 ALB CNTN1 EGR2 GJB1 KIF5A MBP
4 hearing/vestibular/ear MP:0005377 9.8 AQP4 EGR2 KIF5A MAG MBP PMP22
5 vision/eye MP:0005391 9.73 AQP4 CNTN1 CNTNAP1 EGR2 GJB1 KIF5A
6 mortality/aging MP:0010768 9.47 ALB AQP4 CNTN1 CNTNAP1 EGR2 GJB1

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulin G Phase 4
2
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
3 Immunoglobulins, Intravenous Phase 3
4 Immunoglobulins Phase 3
5 Antibodies Phase 3
6 gamma-Globulins Phase 3
7 Rho(D) Immune Globulin Phase 3
8
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
9
Melphalan Approved Phase 2 148-82-3 4053 460612
10
Carmustine Approved, Investigational Phase 2 154-93-8 2578
11
Etoposide Approved Phase 2 33419-42-0 36462
12
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
13
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
14
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
15
Rituximab Approved Phase 2 174722-31-7
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
17
Lipoic acid Approved, Investigational, Nutraceutical Phase 2 1200-22-2 864 6112
18
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 253 171548
19
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
20
Cortisone Experimental Phase 2 53-06-5 222786
21 Autoantibodies Phase 2
22 Vitamins Phase 2
23 Alpha-lipoic Acid Phase 2
24 Folate Phase 2
25 Vitamin B9 Phase 2
26 Trace Elements Phase 2
27 Vitamin B Complex Phase 2
28 Antioxidants Phase 2
29 Micronutrients Phase 2
30 Protective Agents Phase 2
31 Vitamin B7 Phase 2
32 Thymoglobulin Phase 2
33 Antineoplastic Agents, Hormonal Phase 2
34 glucocorticoids Phase 2
35 Anti-Inflammatory Agents Phase 2
36 Antiviral Agents Phase 2
37 Anti-Infective Agents Phase 2
38
Etoposide phosphate Phase 2 16760419
39 Antimitotic Agents Phase 2
40 Keratolytic Agents Phase 2
41 Nitrogen Mustard Compounds Phase 2
42 Antimetabolites Phase 2
43 Antilymphocyte Serum Phase 2
44 Tubulin Modulators Phase 2
45 Dermatologic Agents Phase 2
46 Antibodies, Monoclonal Phase 2
47 Antineoplastic Agents, Immunological Phase 2
48 Complement System Proteins Phase 2
49
D-Alanine Experimental, Nutraceutical Phase 2 302-72-7, 338-69-2, 56-41-7 101757026 602 71080 5950
50
Rozanolixizumab Investigational 1584645-37-3

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy Recruiting NCT04589299 Phase 4
3 Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP Recruiting NCT03684018 Phase 4
4 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
5 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
6 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
7 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
8 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
9 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
10 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
11 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
12 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
13 Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT05327114 Phase 2, Phase 3 Nipocalimab;Placebo
14 Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Not yet recruiting NCT04929236 Phase 3 Panzyga
15 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Completed NCT03864185 Phase 2
16 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
17 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
18 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Completed NCT00278629 Phase 2
19 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
20 A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04658472 Phase 2 SAR445088 (IV);SAR445088 (SC)
21 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04280718 Phase 2
22 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
23 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
24 A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT05581199 Phase 2 Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly;Batoclimab 340 mg SC weekly;Placebo
25 Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Not yet recruiting NCT04480450 Phase 2 Rituximab
26 Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT04881682 Phase 2
27 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
28 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
29 The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration Recruiting NCT05584631 Phase 1 Intravenous immune globulin G;Subcutaneous immune globulin G
30 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
31 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
32 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Completed NCT03008733
33 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
34 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT02465359 Immune Globulin Subcutaneous (Human)
35 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) Completed NCT02414490 Intravenous Immunoglobulin
36 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
37 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
38 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT03772717
39 Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases Recruiting NCT05257733
40 A Registered Cohort Study of Immune-Mediated Neuropathies Recruiting NCT04292834
41 A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives Recruiting NCT01931644
42 Hizentra® in Inflammatory Neuropathies - pHeNIx Study Recruiting NCT04672733
43 Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy Recruiting NCT05011006
44 CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) Available NCT05014724 Rozanolixizumab
45 Study of Connected Soles With Pressure Sensors in the Evaluation of Gait Disorders in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Not yet recruiting NCT05492604
46 Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Among Patients Attending Neuropsychiatry Department - Assiut University Not yet recruiting NCT05219383
47 An Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCs for the Treatment of a Single Patient With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No longer available NCT04825626
48 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Terminated NCT03779828

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

Organs/tissues related to Demyelinating Polyneuropathy:

MalaCards : Spinal Cord, Bone Marrow, Brain, T Cells, Dorsal Root Ganglion, Skeletal Muscle, Lymph Node

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 3002)
# Title Authors PMID Year
1
Novel genes bearing mutations in rare cases of early-onset ataxia with cerebellar hypoplasia. 62 5
35351988 2022
2
ALS Regional Variants (Brachial Amyotrophic Diplegia and Amyotrophic Leg Diplegia): Still A Diagnostic Challenge in Neurology. 62
36474455 2023
3
Identical late motor responses in early Guillain-Barré syndrome: A-waves and Repeater F-waves. 62
36453598 2022
4
Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy. 62
36217677 2022
5
Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy. 62
36190956 2022
6
Disease activity in chronic inflammatory demyelinating polyneuropathy: A comparative study of clinical and skin biopsy markers. 62
36151750 2022
7
Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. 62
36150842 2022
8
Chronic inflammatory demyelinating polyneuropathy: Reconciling guideline updating with increasing disease complexity. 62
36423488 2022
9
Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy. 62
36401951 2022
10
[Clinical and neurophysiological patterns of early presenting symptoms in acute onset chronic inflammatory demyelinating polyradiculoneuropathy]. 62
36440746 2022
11
Immunoglobulin Use for the Management of Painful Peripheral Neuropathy: A Systematic Review and Meta-Analysis. 62
35925489 2022
12
18 F-Fluorodeoxy Glucose and 11 C-Methionine Accumulation in Demyelinating Lesions. 62
36398309 2022
13
Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia. 62
36357291 2022
14
Adult-onset Krabbe disease presenting as isolated sensorimotor demyelinating polyneuropathy: A case report. 62
36057781 2022
15
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up. 62
36083713 2022
16
Miller-Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report. 62
36384584 2022
17
Implantable Electroceutical Approach Improves Myelination by Restoring Membrane Integrity in a Mouse Model of Peripheral Demyelinating Neuropathy. 62
35975427 2022
18
Lewis-Sumner syndrome: contribution of diffusion tensor imaging in its differential diagnosis. 62
36380244 2022
19
Spectrum of Neurological Complications Following COVID-19 Vaccination in India. 62
36367066 2022
20
Combined Central and Peripheral Demyelination in a Case With Sjogren Syndrome. 62
35051965 2022
21
Treatment of chronic inflammatory demyelinating polyneuropathy. 62
35994242 2022
22
Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia. 62
36054471 2022
23
Diagnosis of chronic inflammatory demyelinating polyneuropathy. 62
36259623 2022
24
Chronic inflammatory demyelinating polyneuropathy with positive anti-myelin associated glycoprotein antibodies: Back to clinical basics. 62
36409135 2022
25
Establishment of a new classification system for chronic inflammatory demyelinating polyneuropathy based on unsupervised machine learning. 62
36054019 2022
26
Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial. 62
36057106 2022
27
A first case of childhood chronic inflammatory demyelinating polyneuropathy associated with alopecia universalis. 62
35970688 2022
28
Role of lymphocyte-related immune-inflammatory biomarkers in detecting early progression of Guillain-Barré syndrome. 62
36063751 2022
29
Neurological Complications Following COVID-19 Vaccination. 62
36445631 2022
30
Guillain-Barré syndrome in children - High occurrence of Miller Fisher syndrome in East Asian region. 62
35906115 2022
31
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy. 62
36329046 2022
32
Study of total duration of distal compound muscle action potential in demyelinating and axonal Guillain-Barre' syndrome. 62
36403142 2022
33
Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates. 62
36430700 2022
34
Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report. 62
36324078 2022
35
Outcomes in Guillain-Barré Syndrome following a second therapeutic cycle - A single-centre retrospective observational study. 62
35932547 2022
36
Screening for SH3TC2 variants in Charcot-Marie-Tooth disease in a cohort of Chinese patients. 62
33587240 2022
37
Myoclonus and tremor in chronic inflammatory demyelinating polyneuropathy: a multichannel electromyography analysis. 62
35750953 2022
38
MR neurography of lumbosacral nerve roots for differentiating chronic inflammatory demyelinating polyneuropathy from acquired axonal polyneuropathies: a cross-sectional study. 62
36185044 2022
39
A Case of Pseudogout Causing Thoracic Myelopathy. 62
36381947 2022
40
[A Case of Hirayama Disease Presenting Horn Hand: Spinal Horn Hand]. 62
36198647 2022
41
Autoimmune nodopathies, an emerging diagnostic category. 62
35989582 2022
42
Treatment of CIDP. 62
36109154 2022
43
IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune Nodopathy. 62
35948442 2022
44
A Bioelectrical Impedance Analysis for the Assessment of Muscle Atrophy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. 62
36171120 2022
45
SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath. 62
36127144 2022
46
COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study. 62
35553393 2022
47
Anti-Asialo GM1 Antibody-Positive Optic Neuritis and Optic Perineuritis in Chronic Inflammatory Demyelinating Polyneuropathy. 62
35234692 2022
48
A Response to: Letter to the Editor regarding "COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study". 62
35842565 2022
49
Letter to the Editor regarding "COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study". 62
35841517 2022
50
Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. 62
35638376 2022

Variations for Demyelinating Polyneuropathy

ClinVar genetic disease variations for Demyelinating Polyneuropathy:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LRCH2 NM_020871.4(LRCH2):c.772A>G (p.Lys258Glu) SNV Pathogenic
1342852 GRCh37: X:114414082-114414082
GRCh38: X:115179519-115179519
2 KIF5A NM_004984.4(KIF5A):c.839G>A (p.Arg280His) SNV Pathogenic
37130 rs387907288 GRCh37: 12:57963058-57963058
GRCh38: 12:57569275-57569275
3 KIF5A NM_004984.4(KIF5A):c.2005G>A (p.Ala669Thr) SNV Uncertain Significance
816537 rs142495781 GRCh37: 12:57969522-57969522
GRCh38: 12:57575739-57575739

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 paranode region of axon GO:0033270 9.56 MAG CNTNAP1
2 paranodal junction GO:0033010 9.46 NFASC CNTNAP1
3 myelin sheath GO:0043209 9.43 MPZ MBP MAG
4 compact myelin GO:0043218 9.1 PMP22 MBP MAG

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of myelination GO:0031643 9.73 EGR2 MAG SOX10
2 central nervous system myelin formation GO:0032289 9.62 MAG CNTN1
3 peripheral nervous system development GO:0007422 9.56 SOX10 PMP22 NFASC EGR2
4 central nervous system myelination GO:0022010 9.55 SOX10 MAG CNTNAP1
5 myelination GO:0042552 9.4 PMP22 NFASC MPZ MBP MAG EGR2

Sources for Demyelinating Polyneuropathy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....